ODAIA has raised $15 million in Series C financing to expand its predictive commercial intelligence platform for pharmaceutical companies. Monograph Capital led the round, with strategic participation from PHM, Publicis Groupe’s U.S. health media agency. Existing investors BDC Capital, Flint Capital, Innospark Ventures, Graphite Ventures, Threshold Ventures, and Wittington Ventures also participated.
ODAIA plans to use the funding to expand within its existing enterprise pharmaceutical customers and continue developing its commercial intelligence technology.
Alongside the financing, the company signed a platform agreement making PHM its exclusive U.S. agency partner.
Coordinating Brand, Marketing And Field Sales
Pharmaceutical companies often hold data in separate systems controlled by brand, marketing, analytics, and field-sales teams.
This fragmentation can produce different views of the same healthcare professional and make it difficult to determine which activities influence prescribing behavior.
ODAIA’s platform combines patient, healthcare professional, digital engagement, and field-sales signals into a unified commercial intelligence layer.
The technology predicts patient journeys, identifies potential missed prescription opportunities, prioritizes healthcare professionals, and recommends the channels and messages pharmaceutical companies should use.
Brand teams establish strategy in ODAIA’s Brand Strategy Studio. The platform then converts that strategy into individual recommendations about which healthcare professionals to contact, when to contact them, which channel to use, and what message to communicate.
Field Intelligence delivers prioritized call plans through the pharmaceutical company’s existing customer relationship management system. Marketing Intelligence coordinates individualized professional journeys across digital and partner channels.
ODAIA says the platform can identify physicians whose patients may need a therapy months before a formal diagnosis appears in available data. These are predictive recommendations rather than clinical diagnoses, and their performance will depend on the relevant data and models.
Scaling Technology Across Pharmaceutical Portfolios
ODAIA’s central proposition is that pharmaceutical companies should be able to extend commercial AI across multiple products without building an entirely new system for every brand or therapeutic area.
The platform treats expansion as a configuration process, allowing customers to reuse underlying infrastructure while adapting strategies and rules.
Each recommendation includes an explanation intended to help commercial and compliance teams understand why the system proposed an action.
Users can also ask questions in plain language and receive completed analyses. The platform measures engagement and prescription lift and incorporates observed results into subsequent decisions.
ODAIA will continue selling directly to pharmaceutical companies. Its technology operates alongside existing CRM systems, internal analytics models, and data infrastructure.
The PHM partnership will connect digital media signals with field-sales activity so customers can coordinate healthcare professional engagement across both areas.
Founded at the University of Toronto in 2018, ODAIA is headquartered in Toronto and operates an office in Boston.
KEY QUOTES:
Pharma has proven that AI works in commercial. The hard part now is scaling it. Most companies can show results on one brand, and every new brand or therapeutic area still costs another team and another build. ODAIA started by helping field teams decide where to focus. Today our platform is the commercial intelligence infrastructure that scales what’s working across brand, marketing, and field teams, and across a company’s whole portfolio. This round lets us go deeper with the enterprise customers we already serve and, with PHM, bring that infrastructure to more of the industry, faster.
Philip Poulidis, Co-Founder and CEO of ODAIA
We have watched the ODAIA team turn predictive AI into decisions that pharma brand and field teams act on every day. The ODAIA team has a track record of helping large and specialty pharma brands reach the physicians whose patients need their therapies most.
Charles Conn, Co-Founder and Partner at Monograph Capital

